Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
Last trade$6.05
Day change+$0.035 (+0.58%)
Day range$5.81 – $6.30
Volume2,918,760
Market cap$1.32B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.32B
Price / earnings
—
Price / book
3×
Price / sales
26.23×
EV / sales
17.16×
EV / EBITDA
-2.57×
Profitability
Earnings per share
-$1.49
Return on assets
-53.96%
Return on equity
-74.12%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.17×
Current ratio
9.12×
Quick ratio
9.05×
Cash ratio
8.42×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$267.04M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for OCUL, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$12.87M
$13.48M
$10.79M
$13.25M
$14.54M
$13.46M
$10.7M
$17.08M
Cost of revenue
$1.46M
$2.01M
$1.33M
$1.59M
$1.77M
$1.94M
$1.26M
$1.23M
Gross profit
$11.42M
$11.46M
$9.46M
$11.66M
$12.77M
$11.52M
$9.44M
$15.85M
Selling, general and administrative
$34.49M
$39.44M
$36.58M
$30.62M
$29.11M
$28.08M
$30.5M
$25.44M
Research and development
$74.79M
$54.14M
$66.21M
$50.8M
$52.36M
$51.08M
$42.86M
$40.99M
Total operating expenses
$109.28M
$93.57M
$102.8M
$81.42M
$81.47M
$79.16M
$73.35M
$66.43M
Operating income
-$97.86M
-$82.11M
-$93.34M
-$69.76M
-$68.7M
-$67.64M
-$63.92M
-$50.58M
Interest expense
-$2.81M
-$2.79M
-$2.78M
-$2.83M
-$3M
-$3.02M
-$2.98M
-$3.11M
Income before taxes
-$94.78M
-$78.76M
-$88.61M
-$64.65M
-$69.42M
-$67.81M
-$64.05M
-$48.39M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$94.78M
-$78.76M
-$88.61M
-$64.65M
-$69.42M
-$67.81M
-$64.05M
-$48.39M
Net income attributable to common shareholders
-$94.78M
-$78.76M
-$88.61M
-$64.65M
-$69.42M
-$67.81M
-$64.05M
-$48.39M
EBITDA
-$95.43M
-$80.26M
-$92.06M
-$68.51M
-$67.63M
-$66.62M
-$62.94M
-$49.63M
Basic earnings per share
-$0.42
-$0.35
-$0.40
-$0.29
-$0.38
-$0.39
-$0.38
-$0.29
Diluted earnings per share
-$0.42
-$0.35
-$0.40
-$0.29
-$0.38
-$0.39
-$0.38
-$0.29
Recent news
Company coverage with links to the original publishers.
Ocular Therapeutix (OCUL) reported a quarterly loss of $0.42 per share, missing the consensus estimate of $0.36, and posted revenues of $12.87 million, below the expected $13.78 million. The stock has declined 45.7% year-to-date and carries a Zacks Rank #3 (Hold) rating. The company is expected to post a loss of $0.37 per share next quarter with $13.78 million in revenues.
Ocular Therapeutix, Inc. announced the grant of inducement equity awards to eight newly hired non-executive employees on November 2, 2026. The awards consist of stock options to purchase 35,775 shares at $6.73 per share and restricted stock units for 11,725 shares. The grants were made under the company's 2019 Inducement Stock Incentive Plan in compliance with Nasdaq regulations.
Corcept Therapeutics reported Q3 2026 earnings of $1.01 per share, beating consensus estimates of $0.68 per share, with a 48.53% earnings surprise. Revenues reached $340.47 million, surpassing estimates by 3.43% compared to $207.64 million year-ago. The stock has gained 131.2% year-to-date. However, the company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
A comprehensive pipeline analysis reveals over 50 companies developing 55+ drugs for diabetic retinopathy treatment. Key developments include Kodiak Sciences' Tarcocimab tedromer (Phase III anti-VEGF therapy), Vantage Biosciences' VX-01 (Phase II oral treatment), and Therini Bio's THN391 (Phase I fibrin-targeting therapy). The report covers therapeutic assessments across various development stages, routes of administration, and molecule types, highlighting emerging opportunities in retinal disease treatment.
Ocular Therapeutix announced its participation in multiple scientific conferences in July 2026, including the OIS Retina Innovation Summit and ASRS 44th Annual Meeting in Montreal. The company will present Phase 3 SOL-1 trial results for AXPAXLI (OTX-TKI), its investigational intravitreal axitinib hydrogel for neovascular age-related macular degeneration, along with real-world treatment utilization data. The company will also participate in the HC Wainwright 6th Annual Ophthalmology Virtual Conference on July 22, 2026.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.